A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits

Atherosclerosis
Toshio HayashiLouis J Ignarro

Abstract

The remarkable anti-atherosclerotic effects of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor have not been demonstrated in diet induced severe hyperlipidemia in rabbit model. We have investigated the effect of pitavastatin, a newly developed statin, on atherosclerosis in rabbits. Oophorectomized female NZW rabbits were fed 0.3% cholesterol chow for 12 weeks with or without pitavastatin (0.1mg/kg per day) (Gp.NK and HCD). The level of serum cholesterol was decreased in Gp.NK compared with Gp.HCD (772.8 +/- 70.2 versus 1056.9 +/- 108.3 mg/d), whereas no significant alterations were observed in triglyceride and HDL-cholesterol. NO dependent response stimulated by acetylcholine and calcium ionophore A23187 and tone related basal NO response induced by N(G)-monomethyl-l-arginine acetate were all improved by pitavastatin treatment. Pitavastatin treatment increased the level of cyclic GMP in the aorta of cholesterol fed rabbits. In the aorta, the expression of eNOS mRNA was significantly up regulated and O(2)(-) production was slightly reduced in Gp.NK animals. Atherosclerotic area was significantly decreased in aortic arch and thoracic aorta from Gp.NK compared with those from Gp.HCD ( 15.1 +/- 5.3 versus 41.9 +/- 10.2%, 3.1 +/...Continue Reading

References

Dec 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·T HayashiG Chaudhuri
Feb 1, 1990·Nature·J L Goldstein, M S Brown
Feb 1, 1994·Proceedings of the National Academy of Sciences of the United States of America·C R WhiteB A Freeman
Jan 1, 1993·Free Radical Research Communications·R E Huie, S Padmaja
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·C R WhiteB A Freeman
Sep 3, 1998·The Journal of Biological Chemistry·U Laufs, J K Liao
Sep 2, 1999·Stroke; a Journal of Cerebral Circulation·C J Vaughan, N Delanty
Jan 5, 2002·Journal of the American College of Nutrition·F L Crane
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group

❮ Previous
Next ❯

Citations

Dec 2, 2008·Bulletin of Experimental Biology and Medicine·Y I RaginoG A Tolstikov
Jan 16, 2009·Bulletin of Experimental Biology and Medicine·Yu I RaginoG A Tolstikov
Dec 1, 2011·Journal of Food Science and Technology·Gang ChenGui-Zhi Zhang
Nov 28, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Katsumi MiyauchiMasunori Matsuzaki
Oct 30, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroaki TakashimaTakayuki Ito
Nov 21, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Osamu YoshidaToyoaki Murohara
Mar 31, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Marques da Silva
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Toshio HayashiAkihisa Iguchi
Apr 28, 2009·Clinical Therapeutics·Yoshihiko HorimotoHidehiro Kabasawa
Nov 5, 2008·Journal of Atherosclerosis and Thrombosis·Tadashi YamakawaYasuo Terauchi
Jan 14, 2018·Odontology·Chieko KudoUNKNOWN Periodontitis and Atherosclerosis Project-Tokyo and Chiba Consortiums
Mar 20, 2008·Clinical Orthopaedics and Related Research·Kenjiro NishidaYukihide Iwamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.